{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T21:04:46Z","timestamp":1761253486655,"version":"3.40.5"},"reference-count":94,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CHR"],"published-print":{"date-parts":[[2020,11,9]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Studies from high-income countries have reported that even after receiving antiretroviral treatment\n(ART), HIV-infected adults may not achieve normal levels of certain inflammatory markers that are known to be associated\nwith the onset and development of non-communicable diseases.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To examine the relationship between ART and markers of systemic inflammation in HIV\/AIDS patients at an urban antiretroviral clinic in Ghana.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We examined serum levels of high sensitivity CRP (hsCRP), interleukin-6 (IL-6), interleukin-18(IL-18), and tumor necrosis factor-\u03b1 (sTNFR1 and sTNFR2) from 40 HIV infected patients. Kruskal-Wallis Test was used to examine the\ndifferences in markers of systemic inflammation according to the types of ART medication taken. We then utilized generalized additive models (GAM) with non-linear function to examine the association between ART and markers of systemic inflammation after adjusting for potential confounders.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Overall, 30 (75.0%) of the participants received ART and 35 (85%) were female. Kruskal-Wallis Test revealed no\nsignificant differences in the markers of systemic inflammation among the three categories of ART (none, AZT, 3TC,\nEFV\/NVP, and TDF, 3TC\/FTC, EFV\/NVP). In the multivariable-adjusted GAM model, we found a significant but nonlinear association between time since diagnosis and CRP levels (p=0.006).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Although the relatively small sample size limits the scope of the study's findings, these results suggest that individuals on ART need to be screened periodically for the development of chronic conditions. This line of investigation has\nthe potential to influence treatment and clinical guidelines that will improve the quality of care for HIV-infected patients.\n<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570162x18666200817111152","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T08:08:42Z","timestamp":1597738122000},"page":"466-474","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association between Antiretroviral Treatment and Markers of Systemic Inflammation among HIV Patients in Ghana"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2912-8564","authenticated-orcid":true,"given":"Zelalem T.","family":"Haile","sequence":"first","affiliation":[{"name":"Department of Social Medicine, Ohio University Heritage College of Osteopathic Medicine, Dublin OH-43016, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bismark","family":"Sarfo","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Disease Control, University of Ghana School of Public Health, Legon, Ghana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn Y.","family":"Bonney","sequence":"additional","affiliation":[{"name":"Department of Virology, University of Ghana Noguchi Memorial Institute for Medical Research, Legon, Ghana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric A.","family":"Mensah","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Legon, Ghana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selase","family":"Deletsu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Cell and Molecular Biology, University of Ghana, Legon, Ghana"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"journal-title":"HIV Statistics - Global and Regional Trends","key":"ref=1","unstructured":"HIV Statistics - Global and Regional Trends UNICEF"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/1874613601610010034","volume":"10","author":"Kharsany A.B.M.","year":"2016","unstructured":"Kharsany A.B.M.; Karim Q.A.; HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities. Open AIDS J 2016,10,34-48","journal-title":"Open AIDS J"},{"year":"2015","key":"ref=3","unstructured":"Ghana Statistical Service (GSS), Ghana Health Service (GHS), and ICF International2015"},{"journal-title":"Accra: GAC","year":"2016","key":"ref=4","unstructured":"Ghana National HIV and AIDS Strategic Plan 2016-2020 Accra: GAC Ghana AIDS Commission2016"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1001\/jama.2012.2001","volume":"307","author":"Bendavid E.","year":"2012","unstructured":"Bendavid E.; Holmes C.B.; Bhattacharya J.; Miller G.; HIV development assistance and adult mortality in Africa. JAMA 2012,307(19),2060-2067","journal-title":"JAMA"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e1000066","DOI":"10.1371\/journal.pmed.1000066","volume":"6","author":"Brinkhof M.W.G.","year":"2009","unstructured":"Brinkhof M.W.G.; Boulle A.; Weigel R.; Messou E.; Mathers C.; Orrell C.; Dabis F.; Pascoe M.; Egger M.; Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med International Epidemiological Databases to Evaluate AIDS (IeDEA)2009,6(4),e1000066","journal-title":"PLoS Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1097\/QAD.0b013e32834380c1","volume":"25","author":"Pop-Eleches C.","year":"2011","unstructured":"Pop-Eleches C.; Thirumurthy H.; Habyarimana J.P.; Zivin J.G.; Goldstein M.P.; de Walque D.; MacKeen L.; Haberer J.; Kimaiyo S.; Sidle J.; Ngare D.; Bangsberg D.R.; Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS 2011,25(6),825-834","journal-title":"AIDS"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1471-2334-14-122","volume":"14","author":"Hattab S.","year":"2014","unstructured":"Hattab S.; Guihot A.; Guiguet M.; Fourati S.; Carcelain G.; Caby F.; Marcelin A.G.; Autran B.; Costagliola D.; Katlama C.; Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study. BMC Infect Dis 2014,14,122","journal-title":"BMC Infect Dis"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11904-012-0118-8","volume":"9","author":"Hunt P.W.","year":"2012","unstructured":"Hunt P.W.; HIV and inflammation: mechanisms and consequences. Curr HIV\/AIDS Rep 2012,9(2),139-147","journal-title":"Curr HIV\/AIDS Rep"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.3389\/fimmu.2018.02569","volume":"9","author":"Saeidi A.","year":"2018","unstructured":"Saeidi A.; Zandi K.; Cheok Y.Y.; Saeidi H.; Wong W.F.; Lee C.Y.Q.; Cheong H.C.; Yong Y.K.; Larsson M.; Shankar E.M.; T-cell exhaustion in chronic infections: reversing the state of exhaustion and reinvigorating optimal protective immune responses. Front Immunol 2018,9,2569","journal-title":"Front Immunol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1086\/652749","volume":"201","author":"Neuhaus J.","year":"2010","unstructured":"Neuhaus J.; Jacobs D.R.; Baker J.V.; Calmy A.; Duprez D.; La Rosa A.; Kuller L.H.; Pett S.L.; Ristola M.; Ross M.J.; Shlipak M.G.; Tracy R.; Neaton J.D.; Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010,201(12),1788-1795","journal-title":"J Infect Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/imr.12064","volume":"254","author":"Wilson E.M.P.","year":"2013","unstructured":"Wilson E.M.P.; Sereti I.; Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunol Rev 2013,254(1),343-354","journal-title":"Immunol Rev"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e7658","DOI":"10.1371\/journal.pone.0007658","volume":"4","author":"Mavigner M.","year":"2009","unstructured":"Mavigner M.; Delobel P.; Cazabat M.; Dubois M.; L\u2019faqihi-Olive F-E.; Raymond S.; Pasquier C.; Marchou B.; Massip P.; Izopet J.; HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One 2009,4(10),e7658","journal-title":"PLoS One"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/COH.0000000000000241","volume":"11","author":"Boulougoura A.","year":"2016","unstructured":"Boulougoura A.; Sereti I.; HIV infection and immune activation: the role of coinfections. Curr Opin HIV AIDS 2016,11(2),191-200","journal-title":"Curr Opin HIV AIDS"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/imr.12063","volume":"254","author":"Chang C.C.","year":"2013","unstructured":"Chang C.C.; Crane M.; Zhou J.; Mina M.; Post J.J.; Cameron B.A.; Lloyd A.R.; Jaworowski A.; French M.A.; Lewin S.R.; HIV and co-infections. Immunol Rev 2013,254(1),114-142","journal-title":"Immunol Rev"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/infdis\/jir060","volume":"203","author":"Hunt P.W.","year":"2011","unstructured":"Hunt P.W.; Martin J.N.; Sinclair E.; Epling L.; Teague J.; Jacobson M.A.; Tracy R.P.; Corey L.; Deeks S.G.; Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis 2011,203(10),1474-1483","journal-title":"J Infect Dis"},{"key":"ref=17","first-page":"36","volume":"10","author":"Paiardini M.","year":"2008","unstructured":"Paiardini M.; Frank I.; Pandrea I.; Apetrei C.; Silvestri G.; Mucosal immune dysfunction in AIDS pathogenesis. AIDS Rev 2008,10(1),36-46","journal-title":"AIDS Rev"},{"key":"ref=18","first-page":"2","volume":"18","author":"Lane H.C.","year":"2010","unstructured":"Lane H.C.; Pathogenesis of HIV infection: total CD4+ T-cell pool, immune activation, and inflammation. Top HIV Med 2010,18(1),2-6","journal-title":"Top HIV Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2217\/hiv.10.51","volume":"4","author":"Macatangay B.J.","year":"2010","unstructured":"Macatangay B.J.; Rinaldo C.R.; Regulatory T cells in HIV immunotherapy. HIV Ther 2010,4(6),639-647","journal-title":"HIV Ther"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"6825493","DOI":"10.1155\/2017\/6825493","volume":"2017","author":"Sokoya T.","year":"2017","unstructured":"Sokoya T.; Steel H.C.; Nieuwoudt M.; Rossouw T.M.; HIV as a Cause of Immune Activation and Immunosenescence. Mediators Inflamm 2017,2017,6825493","journal-title":"Mediators Inflamm"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/vim.2008.0006","volume":"21","author":"Terzieva V.","year":"2008","unstructured":"Terzieva V.; Regulatory T cells and HIV-1 infection. Viral Immunol 2008,21(3),285-291","journal-title":"Viral Immunol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1086\/339866","volume":"34","author":"Sav\u00e8s M.","year":"2002","unstructured":"Sav\u00e8s M.; Raffi F.; Capeau J.; Rozenbaum W.; Ragnaud J-M.; Perronne C.; Basdevant A.; Leport C.; Ch\u00eane G.; Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis Antiprot\u00e9ases Cohorte (APROCO) Study Group2002,34(10),1396-1405","journal-title":"Clin Infect Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","volume":"20","author":"Brown T.T.","year":"2006","unstructured":"Brown T.T.; Qaqish R.B.; Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006,20(17),2165-2174","journal-title":"AIDS"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1097\/QAD.0b013e328339192f","volume":"24","author":"Lang S.","year":"2010","unstructured":"Lang S.; Mary-Krause M.; Cotte L.; Gilquin J.; Partisani M.; Simon A.; Boccara F.; Bingham A.; Costagliola D.; Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS French Hospital Database on HIV-ANRS CO42010,24(8),1228-1230","journal-title":"AIDS"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/ijc.25903","volume":"129","author":"Lanoy E.","year":"2011","unstructured":"Lanoy E.; Spano J-P.; Bonnet F.; Guiguet M.; Bou\u00e9 F.; Cadranel J.; Carcelain G.; Couderc L.J.; Frange P.; Girard P.M.; Oksenhendler E.; Poizot-Martin I.; Semaille C.; Agut H.; Katlama C.; Costagliola D.; The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J Cancer ONCOVIH study group2011,129(2),467-475","journal-title":"Int J Cancer"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.beem.2010.10.018","volume":"25","author":"Worm S.W.","year":"2011","unstructured":"Worm S.W.; Lundgren J.D.; The metabolic syndrome in HIV. Best Pract Res Clin Endocrinol Metab 2011,25(3),479-486","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/01.qai.0000243093.34652.41","volume":"43","author":"Jacobson DL","year":"1999","unstructured":"Jacobson DL; Tang AM; Spiegelman D; Thomas AM; Skinner S; Gorbach SL; Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey) J Acquir Immune Defic Syndr 1999 1999,43(4),458-66","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1097\/QAD.0b013e3282efad32","volume":"21","author":"Wand H.","year":"2007","unstructured":"Wand H.; Calmy A.; Carey D.L.; Samaras K.; Carr A.; Law M.G.; Cooper D.A.; Emery S.; Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS INITIO Trial International Coordinating Committee2007,21(18),2445-2453","journal-title":"AIDS"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1097\/QAD.0b013e32832c1792","volume":"23","author":"Grund B.","year":"2009","unstructured":"Grund B.; Peng G.; Gibert C.L.; Hoy J.F.; Isaksson R.L.; Shlay J.C.; Martinez E.; Reiss P.; Visnegarwala F.; Carr A.D.; Continuous antiretroviral therapy decreases bone mineral density. AIDS INSIGHT SMART Body Composition Substudy Group2009,23(12),1519-1529","journal-title":"AIDS"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1210\/jc.2006-0127","volume":"91","author":"Dolan S.E.","year":"2006","unstructured":"Dolan S.E.; Kanter J.R.; Grinspoon S.; Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2006,91(8),2938-2945","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1468-1293.2007.00525.x","volume":"9","author":"Rivas P.","year":"2008","unstructured":"Rivas P.; G\u00f3rgolas M.; Garc\u00eda-Delgado R.; D\u00edaz-Curiel M.; Goyenechea A.; Fern\u00e1ndez-Guerrero M.L.; Evolution of bone mineral density in AIDS patients on treatment with zidovudine\/lamivudine plus abacavir or lopinavir\/ritonavir. HIV Med 2008,9(2),89-95","journal-title":"HIV Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"e0227893","DOI":"10.1371\/journal.pone.0227893","volume":"15","author":"Chisati E.M.","year":"2020","unstructured":"Chisati E.M.; Constantinou D.; Lampiao F.; Reduced bone mineral density among HIV infected patients on anti-retroviral therapy in Blantyre, Malawi: Prevalence and associated factors. PLoS One 2020,15(1),e0227893","journal-title":"PLoS One"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4103\/jgid.jgid_4_18","volume":"11","author":"Jarwani B.","year":"2019","unstructured":"Jarwani B.; Cardiovascular Disease and Antiretroviral Therapy. J Glob Infect Dis 2019,11(3),91-92","journal-title":"J Glob Infect Dis"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMoa030218","volume":"349","author":"Friis-M\u00f8ller N.","year":"2003","unstructured":"Friis-M\u00f8ller N.; Sabin C.A.; Weber R.; d\u2019Arminio Monforte A.; El-Sadr W.M.; Reiss P.; Thi\u00e9baut R.; Morfeldt L.; De Wit S.; Pradier C.; Calvo G.; Law M.G.; Kirk O.; Phillips A.N.; Lundgren J.D.; Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group2003,349(21),1993-2003","journal-title":"N Engl J Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1097\/QAD.0b013e32833d2132","volume":"24","author":"Delaney J.A.C.","year":"2010","unstructured":"Delaney J.A.C.; Scherzer R.; Biggs M.L.; Shliplak M.G.; Polak J.F.; Currier J.S.; Kronmal R.A.; Wanke C.; Bacchetti P.; O\u2019leary D.; Tien P.C.; Grunfeld C.; Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness. AIDS 2010,24(14),2201-2209","journal-title":"AIDS"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/cid\/civ316","volume":"61","author":"Desai M.","year":"2015","unstructured":"Desai M.; Joyce V.; Bendavid E.; Olshen R.A.; Hlatky M.; Chow A.; Holodniy M.; Barnett P.; Owens D.K.; Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population. Clin Infect Dis 2015,61(3),445-452","journal-title":"Clin Infect Dis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1086\/649897","volume":"201","author":"Worm S.W.","year":"2010","unstructured":"Worm S.W.; Sabin C.; Weber R.; Reiss P.; El-Sadr W.; Dabis F.; De Wit S.; Law M.; Monforte A.D.; Friis-M\u00f8ller N.; Kirk O.; Fontas E.; Weller I.; Phillips A.; Lundgren J.; Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010,201(3),318-330","journal-title":"J Infect Dis"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1097\/QAD.0b013e32835935b3","volume":"26","author":"Chao C.","year":"2012","unstructured":"Chao C.; Leyden W.A.; Xu L.; Horberg M.A.; Klein D.; Towner W.J.; Quesenberry C.P.; Abrams D.I.; Silverberg M.J.; Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS 2012,26(17),2223-2231","journal-title":"AIDS"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"e0142966","DOI":"10.1371\/journal.pone.0142966","volume":"10","author":"Mbang P.A.","year":"2015","unstructured":"Mbang P.A.; Kowalkowski M.A.; Amirian E.S.; Giordano T.P.; Richardson P.A.; Hartman C.M.; Chiao E.Y.; Association between time on protease inhibitors and the incidence of squamous cell carcinoma of the anus among U.S. male veterans. PLoS One 2015,10(12),e0142966","journal-title":"PLoS One"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1086\/518606","volume":"45","author":"Kirk G.D.","year":"2007","unstructured":"Kirk G.D.; Merlo C.; O\u2019 Driscoll P.; Mehta S.H.; Galai N.; Vlahov D.; Samet J.; Engels E.A.; HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007,45(1),103-110","journal-title":"Clin Infect Dis"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1097\/QAD.0b013e3282ed6338","volume":"21","author":"Silverberg M.J.","year":"2007","unstructured":"Silverberg M.J.; Neuhaus J.; Bower M.; Gey D.; Hatzakis A.; Henry K.; Hidalgo J.; Lourtau L.; Neaton J.D.; Tambussi G.; Abrams D.I.; Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007,21(14),1957-1963","journal-title":"AIDS"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"e81355","DOI":"10.1371\/journal.pone.0081355","volume":"8","author":"Samji H.","year":"2013","unstructured":"Samji H.; Cescon A.; Hogg R.S.; Modur S.P.; Althoff K.N.; Buchacz K.; Burchell A.N.; Cohen M.; Gebo K.A.; Gill M.J.; Justice A.; Kirk G.; Klein M.B.; Korthuis P.T.; Martin J.; Napravnik S.; Rourke S.B.; Sterling T.R.; Silverberg M.J.; Deeks S.; Jacobson L.P.; Bosch R.J.; Kitahata M.M.; Goedert J.J.; Moore R.; Gange S.J.; Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One 2013,8(12),e81355","journal-title":"PLoS One"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/ije\/dyr164","volume":"41","author":"Lewden C.","year":"2012","unstructured":"Lewden C.; Bouteloup V.; De Wit S.; Sabin C.; Mocroft A.; Wasmuth J.C.; van Sighem A.; Kirk O.; Obel N.; Panos G.; Ghosn J.; Dabis F.; Mary-Krause M.; Leport C.; Perez-Hoyos S.; Sobrino-Vegas P.; Stephan C.; Castagna A.; Antinori A.; d\u2019Arminio Monforte A.; Torti C.; Mussini C.; Isern V.; Calmy A.; Teira R.; Egger M.; Grarup J.; Ch\u00eane G.; All-cause mortality in treated HIV-infected adults with CD4 \u2265500\/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012,41(2),433-445","journal-title":"Int J Epidemiol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","volume":"372","year":"2008","unstructured":"Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet Antiretroviral Therapy Cohort Collaboration2008,372(9635),293-299","journal-title":"Lancet"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/cid\/cir627","volume":"53","author":"Guaraldi G.","year":"2011","unstructured":"Guaraldi G.; Orlando G.; Zona S.; Menozzi M.; Carli F.; Garlassi E.; Berti A.; Rossi E.; Roverato A.; Palella F.; Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011,53(11),1120-1126","journal-title":"Clin Infect Dis"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.2105\/AJPH.2009.188664","volume":"100","author":"Lifson A.R.","year":"2010","unstructured":"Lifson A.R.; Neuhaus J.; Arribas J.R.; van den Berg-Wolf M.; Labriola A.M.; Read T.R.H.; Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health INSIGHT SMART Study Group2010,100(10),1896-1903","journal-title":"Am J Public Health"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1741-7015-11-16","volume":"11","author":"Petrosillo N.","year":"2013","unstructured":"Petrosillo N.; Cicalini S.; Smoking and HIV: time for a change? BMC Med 2013,11,16","journal-title":"BMC Med"},{"key":"ref=48","first-page":"17","volume":"8","author":"Kariuki W.","year":"2015","unstructured":"Kariuki W.; Manuel J.I.; Kariuki N.; Tuchman E.; O\u2019Neal J.; Lalanne G.A.; HIV and smoking: associated risks and prevention strategies. HIV AIDS (Auckl) 2015,8,17-36","journal-title":"HIV AIDS (Auckl)"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","volume":"356","author":"Carr A.","year":"2000","unstructured":"Carr A.; Cooper D.A.; Adverse effects of antiretroviral therapy. Lancet 2000,356(9239),1423-1430","journal-title":"Lancet"},{"key":"ref=50","first-page":"1443","volume":"83","author":"Reust C.E.","year":"2011","unstructured":"Reust C.E.; Common adverse effects of antiretroviral therapy for HIV disease. Am Fam Physician 2011,83(12),1443-1451","journal-title":"Am Fam Physician"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1097\/INF.0000000000000663","volume":"34","author":"Fortuny C.","year":"2015","unstructured":"Fortuny C.; Dey\u00e0-Mart\u00ednez \u00c1.; Chiappini E.; Galli L.; de Martino M.; Noguera-Julian A.; Metabolic and renal adverse effects of antiretroviral therapy in HIV-infected children and adolescents. Pediatr Infect Dis J 2015,34(5)(Suppl. 1),S36-S43","journal-title":"Pediatr Infect Dis J"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.antiviral.2009.10.016","volume":"85","author":"Hawkins T.","year":"2010","unstructured":"Hawkins T.; Understanding and managing the adverse effects of antiretroviral therapy. Antiviral Res 2010,85(1),201-209","journal-title":"Antiviral Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2174\/187152908786786232","volume":"8","author":"Filardi P.P.","year":"2008","unstructured":"Filardi P.P.; Paolillo S.; Marciano C.; Iorio A.; Losco T.; Marsico F.; Scala O.; Ruggiero D.; Ferraro S.; Chiariello M.; Cardiovascular effects of antiretroviral drugs: clinical review. Cardiovasc Hematol Disord Drug Targets 2008,8(4),238-244","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/QAI.0b013e3181e0cdea","volume":"54","author":"Redd AD","year":"1999","unstructured":"Redd AD; Eaton KP; Kong X; Laeyendecker O; Lutalo T; Wawer MJ; C-reactive protein levels increase during HIV-1 disease progression in Rakai, Uganda despite the absence of microbial translocation J Acquir Immune Defic Syndr 1999 1999,54(5),556-9","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1001\/archinte.166.1.64","volume":"166","author":"Lau B.","year":"2006","unstructured":"Lau B.; Sharrett A.R.; Kingsley L.A.; Post W.; Palella F.J.; Visscher B.; Gange S.J.; C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006,166(1),64-70","journal-title":"Arch Intern Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/infdis\/jiw173","volume":"214","author":"Borges \u00c1.H.","year":"2016","unstructured":"Borges \u00c1.H.; O\u2019Connor J.L.; Phillips A.N.; Neaton J.D.; Grund B.; Neuhaus J.; Vjecha M.J.; Calmy A.; Koelsch K.K.; Lundgren J.D.; Interleukin 6 is a stronger predictor of clinical events than high-sensitivity C-Reactive protein or D-Dimer during HIV infection. J Infect Dis INSIGHT SMART Study and ESPRIT Groups2016,214(3),408-416","journal-title":"J Infect Dis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/COH.0b013e32833ed75d","volume":"5","author":"Neaton J.D.","year":"2010","unstructured":"Neaton J.D.; Neuhaus J.; Emery S.; Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. Curr Opin HIV AIDS 2010,5(6),480-490","journal-title":"Curr Opin HIV AIDS"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"e0155100","DOI":"10.1371\/journal.pone.0155100","volume":"11","author":"Grund B.","year":"2016","unstructured":"Grund B.; Baker J.V.; Deeks S.G.; Wolfson J.; Wentworth D.; Cozzi-Lepri A.; Cohen C.J.; Phillips A.; Lundgren J.D.; Neaton J.D.; Relevance of interleukin-6 and D-Dimer for serious non-AIDS morbidity and death among HIV- positive adults on suppressive antiretroviral therapy. PLoS One INSIGHT SMART\/ESPRIT\/SILCAAT Study Group2016,11(5),e0155100","journal-title":"PLoS One"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/cid\/ciw409","volume":"63","author":"Wada N.I.","year":"2016","unstructured":"Wada N.I.; Bream J.H.; Mart\u00ednez-Maza O.; Macatangay B.; Galvin S.R.; Margolick J.B.; Jacobson L.P.; Inflammatory biomarkers and mortality risk among HIV-suppressed men: A multisite prospective cohort study. Clin Infect Dis 2016,63(7),984-990","journal-title":"Clin Infect Dis"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"12448","DOI":"10.1128\/JVI.76.24.12448-12456.2002","volume":"76","author":"Ahmad R.","year":"2002","unstructured":"Ahmad R.; Sindhu S.T.A.; Toma E.; Morisset R.; Ahmad A.; Elevated levels of circulating interleukin-18 in human immunodeficiency virus-infected individuals: role of peripheral blood mononuclear cells and implications for AIDS pathogenesis. J Virol 2002,76(24),12448-12456","journal-title":"J Virol"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/00126334-200405010-00006","volume":"36","author":"Lindegaard B","year":"1999","unstructured":"Lindegaard B; Hansen A-BE; Gerstoft J; Pedersen BK; High plasma level of interleukin-18 in HIV-infected subjects with lipodystrophy J Acquir Immune Defic Syndr 1999 1999,36(1),588-93","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.micinf.2004.07.009","volume":"6","author":"Wiercinska-Drapalo A.","year":"2004","unstructured":"Wiercinska-Drapalo A.; Jaroszewicz J.; Flisiak R.; Prokopowicz D.; Plasma interleukin-18 is associated with viral load and disease progression in HIV-1-infected patients. Microbes Infect 2004,6(14),1273-1277","journal-title":"Microbes Infect"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01.qai.0000437171.00504.41","volume":"65","author":"McComsey GA","year":"1999","unstructured":"McComsey GA; Kitch D; Sax PE; Tierney C; Jahed NC; Melbourne K; Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of Antiretroviral Therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202 J Acquir Immune Defic Syndr 1999 1999,65(2),167-74","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/infdis\/jit147","volume":"208","author":"Erlandson K.M.","year":"2013","unstructured":"Erlandson K.M.; Allshouse A.A.; Jankowski C.M.; Lee E.J.; Rufner K.M.; Palmer B.E.; Wilson C.C.; MaWhinney S.; Kohrt W.M.; Campbell T.B.; Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis 2013,208(2),249-259","journal-title":"J Infect Dis"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/infdis\/jiu254","volume":"210","author":"Tenorio A.R.","year":"2014","unstructured":"Tenorio A.R.; Zheng Y.; Bosch R.J.; Krishnan S.; Rodriguez B.; Hunt P.W.; Plants J.; Seth A.; Wilson C.C.; Deeks S.G.; Lederman M.M.; Landay A.L.; Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014,210(8),1248-1259","journal-title":"J Infect Dis"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.2337\/dc10-0633","volume":"33","author":"Brown T.T.","year":"2010","unstructured":"Brown T.T.; Tassiopoulos K.; Bosch R.J.; Shikuma C.; McComsey G.A.; Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care 2010,33(10),2244-2249","journal-title":"Diabetes Care"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/QAI.0000000000000354","volume":"67","author":"Dooko CBA","year":"1999","unstructured":"Dooko CBA; De Wit S; Neuhaus J; Palfreeman A; Pepe R; Pankow JS; Interleukin-6, high sensitivity C-Reactive protein, and the development of type 2 diabetes among HIV positive patients taking Antiretroviral Therapy J Acquir Immune Defic Syndr 1999 1999,67(5),538-46","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1038\/s41598-018-24446-4","volume":"8","author":"Vi\u0161kovi\u0107 K.","year":"2018","unstructured":"Vi\u0161kovi\u0107 K.; \u017didovec Lepej S.; Gorenec A.; Grgi\u0107 I.; Lukas D.; Zekan \u0160.; Dragobratovi\u0107 A.; Trupkovi\u0107 M.; Begovac J.; Cardiovascular markers of inflammation and serum lipid levels in HIV-infected patients with undetectable viremia. Sci Rep 2018,8(1),6113","journal-title":"Sci Rep"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1097\/QAD.0000000000001109","volume":"30","author":"Nou E","year":"2016","unstructured":"Nou E; Lo J; Grinspoon SK; Inflammation, immune activation, and cardiovascular disease in HIV AIDS Lond Engl 2016,30(10),1495-509","journal-title":"AIDS Lond Engl"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"e0147484","DOI":"10.1371\/journal.pone.0147484","volume":"11","author":"Vos A.G.","year":"2016","unstructured":"Vos A.G.; Idris N.S.; Barth R.E.; Klipstein-Grobusch K.; Grobbee D.E.; Pro-Inflammatory markers in relation to cardiovascular disease in HIV infection. A systematic review. PLoS One 2016,11(1),e0147484","journal-title":"PLoS One"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"e44454","DOI":"10.1371\/journal.pone.0044454","volume":"7","author":"Duprez D.A.","year":"2012","unstructured":"Duprez D.A.; Neuhaus J.; Kuller L.H.; Tracy R.; Belloso W.; De Wit S.; Drummond F.; Lane H.C.; Ledergerber B.; Lundgren J.; Nixon D.; Paton N.I.; Prineas R.J.; Neaton J.D.; Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One INSIGHT SMART Study Group2012,7(9),e44454","journal-title":"PLoS One"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/QAI.0b013e3181a9992c","volume":"51","author":"Triant VA","year":"1999","unstructured":"Triant VA; Meigs JB; Grinspoon SK; Association of C-reactive protein and HIV infection with acute myocardial infarction J Acquir Immune Defic Syndr 1999 1999,51(3),268-73","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"4697473","DOI":"10.1155\/2017\/4697473","volume":"2017","author":"Sarfo B.","year":"2017","unstructured":"Sarfo B.; Vanderpuye N.A.; Addison A.; Nyasulu P.; HIV case management support service is associated with improved CD4 counts of patients receiving care at the Antiretroviral Clinic of Pantang hospital, Ghana. Aids Res Treat 2017,2017,4697473","journal-title":"Aids Res Treat"},{"journal-title":"Strengthening the Reporting of Observational Studies in Epidemiology","author":"Statement S.T.R.O.B.E.","key":"ref=74","unstructured":"Statement S.T.R.O.B.E.;  Strengthening the Reporting of Observational Studies in Epidemiology"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1476-511X-13-90","volume":"13","author":"Papakonstantinou V.D.","year":"2014","unstructured":"Papakonstantinou V.D.; Chini M.; Mangafas N.; Stamatakis G.M.; Tsogas N.; Tsoupras A.B.; Psarra K.; Fragopoulou E.; Antonopoulou S.; Gargalianos P.; Demopoulos C.A.; Lazanas M.C.; In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients. Lipids Health Dis 2014,13,90","journal-title":"Lipids Health Dis"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"F17","DOI":"10.1097\/QAD.0b013e32830fe35e","volume":"22","year":"2008","unstructured":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS Strategies for Management of Anti-Retroviral Therapy\/INSIGHT2008,22(14),F17-F24","journal-title":"AIDS"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-2334-11-40","volume":"11","author":"Padilla S.","year":"2011","unstructured":"Padilla S.; Masi\u00e1 M.; Garc\u00eda N.; Jarrin I.; Tormo C.; Guti\u00e9rrez F.; Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis 2011,11,40","journal-title":"BMC Infect Dis"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1097\/QAD.0b013e3283389dfa","volume":"24","author":"Palella F.J.","year":"2010","unstructured":"Palella F.J.; Gange S.J.; Benning L.; Jacobson L.; Kaplan R.C.; Landay A.L.; Tracy R.P.; Elion R.; Inflammatory biomarkers and abacavir use in the Women\u2019s Interagency HIV Study and the Multicenter AIDS Cohort Study. AIDS 2010,24(11),1657-1665","journal-title":"AIDS"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1093\/infdis\/jiv004","volume":"212","author":"Hileman C.O.","year":"2015","unstructured":"Hileman C.O.; Kinley B.; Scharen-Guivel V.; Melbourne K.; Szwarcberg J.; Robinson J.; Lederman M.M.; Mccomsey G.A.; Differential reduction in monocyte activation and vascular inflammation with integrase inhibitor-based initial antiretroviral therapy among HIV-infected individuals. J Infect Dis 2015,212(3),345-354","journal-title":"J Infect Dis"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/cid\/civ327","volume":"61","author":"Kelesidis T.","year":"2015","unstructured":"Kelesidis T.; Tran T.T.T.; Stein J.H.; Brown T.T.; Moser C.; Ribaudo H.J.; Dube M.P.; Murphy R.; Yang O.O.; Currier J.S.; McComsey G.A.; Changes in inflammation and immune activation with Atazanavir-, Raltegravir-, Darunavir-based i\tnitial Antiviral Therapy: ACTG 5260s. Clin Infect Dis 2015,61(4),651-660","journal-title":"Clin Infect Dis"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/1471-2334-13-269","volume":"13","author":"Kumar P.","year":"2013","unstructured":"Kumar P.; DeJesus E.; Huhn G.; Sloan L.; Small C.B.; Edelstein H.; Felizarta F.; Hao R.; Ross L.; Stancil B.; Pappa K.; Ha B.; Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir\/ritonavir vs. efavirenz with abacavir\/lamivudine in underrepresented, antiretroviral-na\u00efve, HIV-infected patients (SUPPORT): 96-week results. BMC Infect Dis SUPPORT Study Team2013,13,269","journal-title":"BMC Infect Dis"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.atherosclerosis.2006.12.022","volume":"196","author":"Lorenz M.W.","year":"2008","unstructured":"Lorenz M.W.; Stephan C.; Harmjanz A.; Staszewski S.; Buehler A.; Bickel M.; von Kegler S.; Ruhkamp D.; Steinmetz H.; Sitzer M.; Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 2008,196(2),720-726","journal-title":"Atherosclerosis"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1742-6405-11-32","volume":"11","author":"Gomo Z.A.","year":"2014","unstructured":"Gomo Z.A.; Hakim J.G.; Walker S.A.; Tinago W.; Mandozana G.; Kityo C.; Munderi P.; Katabira E.; Reid A.; Gibb D.M.; Gilks C.F.; Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study. AIDS Res Ther DART Team2014,11(1),32","journal-title":"AIDS Res Ther"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"185","DOI":"10.4103\/0300-1652.114591","volume":"54","author":"Muhammad S.","year":"2013","unstructured":"Muhammad S.; Sani M.U.; Okeahialam B.N.; Cardiovascular disease risk factors among HIV-infected Nigerians receiving highly active antiretroviral therapy. Niger Med J 2013,54(3),185-190","journal-title":"Niger Med J"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2147\/HIV.S78523","volume":"7","author":"Zhou D.T.","year":"2015","unstructured":"Zhou D.T.; Kodogo V.; Chokuona K.F.V.; Gomo E.; Oektedalen O.; Stray-Pedersen B.; Dyslipidemia and cardiovascular disease risk profiles of patients attending an HIV treatment clinic in Harare, Zimbabwe. HIV AIDS (Auckl) 2015,7,145-155","journal-title":"HIV AIDS (Auckl)"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.2147\/TCRM.S117980","volume":"12","author":"Gori E.","year":"2016","unstructured":"Gori E.; Mduluza T.; Nyagura M.; Stray-Pedersen B.; Gomo Z.A.; Inflammation-modulating cytokine profile and lipid interaction in HIV-related risk factors for cardiovascular diseases. Ther Clin Risk Manag 2016,12,1659-1666","journal-title":"Ther Clin Risk Manag"},{"key":"ref=87","first-page":"49","volume":"13","author":"Estrada V.","year":"2011","unstructured":"Estrada V.; Portilla J.; Dyslipidemia related to antiretroviral therapy. AIDS Rev 2011,13(1),49-56","journal-title":"AIDS Rev"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2174\/1874192401105010049","volume":"5","author":"Feeney E.R.","year":"2011","unstructured":"Feeney E.R.; Mallon P.W.G.; HIV and HAART-Associated Dyslipidemia. Open Cardiovasc Med J 2011,5,49-63","journal-title":"Open Cardiovasc Med J"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11883-010-0152-1","volume":"13","author":"Troll J.G.","year":"2011","unstructured":"Troll J.G.; Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection. Curr Atheroscler Rep 2011,13(1),51-56","journal-title":"Curr Atheroscler Rep"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1056\/NEJMoa062360","volume":"355","author":"El-Sadr W.M.","year":"2006","unstructured":"El-Sadr W.M.; Lundgren J.; Neaton J.D.; Gordin F.; Abrams D.; Arduino R.C.; Babiker A.; Burman W.; Clumeck N.; Cohen C.J.; Cohn D.; Cooper D.; Darbyshire J.; Emery S.; F\u00e4tkenheuer G.; Gazzard B.; Grund B.; Hoy J.; Klingman K.; Losso M.; Markowitz N.; Neuhaus J.; Phillips A.; Rappoport C.; CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med Strategies for Management of Antiretroviral Therapy (SMART) Study Group2006,355(22),2283-2296","journal-title":"N Engl J Med"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1371\/journal.pmed.0050203","volume":"5","author":"Kuller L.H.","year":"2008","unstructured":"Kuller L.H.; Tracy R.; Belloso W.; De Wit S.; Drummond F.; Lane H.C.; Ledergerber B.; Lundgren J.; Neuhaus J.; Nixon D.; Paton N.I.; Neaton J.D.; Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med INSIGHT SMART Study Group2008,5(10),e203","journal-title":"PLoS Med"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cca.2009.06.029","volume":"408","author":"Goswami B.","year":"2009","unstructured":"Goswami B.; Rajappa M.; Mallika V.; Shukla D.K.; Kumar S.; TNF-alpha\/IL-10 ratio and C-reactive protein as markers of the inflammatory response in CAD-prone North Indian patients with acute myocardial infarction. Clin Chim Acta 2009,408(1-2),14-18","journal-title":"Clin Chim Acta"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1258\/0956462054094006","volume":"16","author":"Noursadeghi M.","year":"2005","unstructured":"Noursadeghi M.; Miller R.F.; Clinical value of C-reactive protein measurements in HIV-positive patients. Int J STD AIDS 2005,16(6),438-441","journal-title":"Int J STD AIDS"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"868","DOI":"10.2337\/diacare.22.5.868","volume":"22","author":"Fern\u00e1ndez-Real J.M.","year":"1999","unstructured":"Fern\u00e1ndez-Real J.M.; Guti\u00e9rrez C.; Broch M.; Casamitjana R.; Vendrell J.; Ricart W.; Insulin response to intravenous glucose correlates with plasma levels of the tumor necrosis factor receptor-1. Diabetes Care 1999,22(5),868-870","journal-title":"Diabetes Care"}],"container-title":["Current HIV Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/184884","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184884\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/184884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T14:06:13Z","timestamp":1626962773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184884\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":94,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570162x18666200817111152","relation":{},"ISSN":["1570-162X"],"issn-type":[{"type":"print","value":"1570-162X"}],"subject":[],"published":{"date-parts":[[2020,11,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}